Acquisition enhances market access capabilities in the U.S. to support life sciences clients in optimizing the value of their products and accelerating patient access to medical and technological advances
Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in building healthcare businesses, announced today the acquisition of Cyan Health (“Cyan”), a strategic payer marketing agency focused on guiding clients to successful market access for their products. Cyan is the fourth acquisition for Arsenal’s Value Demonstration organization, following the acquisitions of BresMed Health Solutions (“BresMed”) and Cello Health plc (“Cello Health”) in 2020 and Guidemark Health (“Guidemark”) in October 2021.
Arsenal has brought these companies together to create a unique combination of solutions to develop and communicate evidence of value to optimize patient access to new therapies.
U.S.-based Cyan identifies the critical challenges to access, develops the strategy needed for success, creates compelling communications for payers, and establishes how best to implement these in the field with payer customers.
The combined capabilities and experience of Cyan and BresMed will enable clients to understand and shape the value and access landscape, create an integrated value strategy early in the development of a product, generate evidence which demonstrates clear value, drive product access and adoption, and demonstrate value over time.
Jon Williams, CEO of Arsenal’s Value Demonstration business, said: “We are delighted to join forces with Cyan, which is an ideal fit that further enhances our offerings’ market access. We are building a market-leading global company that will develop new and transformative approaches to improve patient health by accelerating and optimizing access to medical advances. We look forward to working with our new colleagues and building a company that better meets the needs of life sciences companies and the patients whom we collectively serve.”
Amber Gilbert, Managing Director of Cyan, said: “We are thrilled to join this pioneering and fast-growing global organization. With our combined capabilities and complementary expertise, we are well-positioned to enable healthcare clients to effectively demonstrate and optimize patient access to important therapies and innovation. This is an exciting new chapter for Cyan, and we look forward to playing a valuable role in the future growth of the business.”
For more information, contact Sally Donovan-Smith, firstname.lastname@example.org, +44 7780464331
About Arsenal’s Value Demonstration Business
Arsenal’s Value Demonstration company was formed following the acquisitions of BresMed and Cello Health in 2020 and of Guidemark Health in 2021. The company offers a differentiated set of capabilities across critical healthcare domains including strategy and insights, evidence generation, data and analytics, and communications – all rooted in world-class science and enabled by the latest technology. It supports clients across the healthcare industry globally, with close to 1000 employees in offices around the world, with the mission to improve patient health by accelerating and optimizing access to effective medical advances. For more information, please visit www.bresmed.com, www.cellohealth.com, www.guidemarkhealth.com and www.cyanhealth.com.
Our priority is hiring and retaining the best and most capable in our field. If you’re interested in finding out about our open roles, you can find out more here:
About Cyan Health
Cyan Health is a strategic agency that optimizes every aspect, phase, and function of the payer engagement process, incorporating market research and strategic consulting with comprehensive agency services. Its integrated service model bridges the gap from insights to action, empowering clients to understand – and engage – targeted decision-makers. Cyan’s services include Strategic Planning, Market Research and Insights Generation, Customer Engagement, and Training and Empowerment. Its diversely experienced team of professionals bring deep knowledge of the evolving market access landscape – informed by extensive experience across a spectrum of disease states and customer channels.
Cyan Health is located in Montclair, New Jersey.
For more information, please visit www.cyanhealth.com.
About Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity firm that specializes in investments in middle‐market industrials and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of more than $7.0 billion, completed more than 200 platform and add-on investments, and achieved more than 30 realizations. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value‐add. For more information, please visit www.arsenalcapital.com.
Arsenal’s Value Demonstration Business Acquires Zipher Medical Affairs. Acquisition further strengthens market-leading medical affairs to support life sciences clients in optimizing the value of their products and accelerating patient access to medical and technological advances.
On 19 November 2021, the MS21 team received a Best Practice award from the Members of the European Parliament (MEP) Interest Group on Brain, Mind and Pain, an initiative of European Federation of Neurological Associations (EFNA) and Pain Alliance Europe.
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us